Why a generic's label must match the brand's, and keep matching

On June 23, 2011, the Supreme Court ruled 5 to 4 that patients who said they were harmed by generic metoclopramide, a digestive drug, could not sue the generic makers under state law for failing to warn them. The reason was a single federal requirement. Federal law, the majority opinion¹ said, "demanded that generic drug labels be the same at all times as the corresponding brand-name drug labels." A generic company that strengthened its own warning would break federal law, so state law could not require it.

That sameness duty governs the package insert, the Medication Guide and the carton of most prescriptions dispensed in the United States. It starts with the application, continues for as long as the generic is sold, and changes every time FDA approves a change to the brand's label.

FDA tried once to loosen it and gave up. This piece covers what the law requires, what can differ, how generic labels are kept current, and what the next user fee agreement would change. GxRadar's separate explainer on skinny labels and carve-outs covers the patent side.

The statute and the rule

Congress wrote the requirement into the law that created the generic pathway. The 1984 Drug Price Competition and Patent Term Restoration Act³, known as Hatch-Waxman, required each abbreviated application to show "that the labeling proposed for the new drug is the same as the labeling approved for the listed drug," with two exceptions. The same words remain in 21 U.S.C. 355(j)(2)(A)(v)⁴, and paragraph (j)(4)(G) lets FDA refuse approval when the applicant has not shown it.

FDA's regulation, 21 CFR 314.94(a)(8)⁵, turns that into paperwork. An applicant must include a copy of the currently approved labeling for the brand, which FDA calls the reference listed drug, a statement that its own labeling is the same "except for differences annotated and explained," and "a side-by-side comparison" of the two. A companion rule, 21 CFR 314.127(a)(7)⁶, makes a failed showing a ground to refuse approval.

FDA's generic drug labeling resources page⁹ puts it in one line. Generic labeling "must be the 'same as' the last approved reference listed drug (RLD) labeling except for permissible differences." The differences explain why a generic's tablets can look nothing like the brand's, a point GxRadar covers in why your pill changed color. The warnings, including any boxed warning, the dosing sections and the indications follow the brand.

How FDA reviews a generic's label

Labeling is one of the review disciplines in FDA's Office of Generic Drugs, alongside bioequivalence and product quality. The GDUFA III commitment letter¹⁵ gives it its own timetable. In the first review cycle, labeling reviewers are to "strive to issue any DRL at approximately months 6-7" for applications with a 10-month goal, and FDA "will minimize issuing CRLs that contain only labeling deficiencies." Applicants that carve out patented uses must say so in the cover letter.

Labeling problems are usually treated as small. FDA's 2024 guidance on ANDA amendments¹³ lists responses to "labeling deficiencies that have not been adequately addressed in response to an IR" among its examples of minor amendments, which carry a three-month review goal, as explained in GxRadar's piece on major and minor deficiencies. Packaging is the exception. FDA's refuse-to-receive guidance¹⁴ says it may refuse an application outright, case by case, if its packaging or labeling differs from the brand's in ways "associated with safe/effective use," such as a blister card that carries patient instructions.

Keeping up after the brand changes

Approval is not the end of the duty. Under 21 CFR 314.150(b)(10)⁷, FDA may withdraw approval of a generic whose labeling "is no longer consistent with that for the listed drug," apart from approved differences. FDA's January 2024 guidance, Revising ANDA Labeling Following Revision of the RLD Labeling¹⁰, says generic holders are "expected to update" after FDA approves brand changes and should "routinely monitor Drugs@FDA" for them. Pending applications update by amendment. Approved ones file a supplement under the change categories in 21 CFR 314.70⁸, with a new side-by-side comparison. FDA's fiscal 2025 activity report¹⁹ counts 9,732 changes-being-effected supplements to generic applications, a category that includes labeling updates among other changes.

Timing problems near approval are handled by section 505(j)(10), which the Affordable Care Act added on March 23, 2010. It lets FDA approve a generic carrying the brand's earlier labeling when the brand's revision came within 90 days of the generic becoming otherwise eligible, the revision did not change the "Warnings" section, and the applicant agrees to submit updated labeling within 60 days of approval. The 90-day window and the 60-day clock come from a December 2022 amendment, according to FDA's internal manual MAPP 5230.3¹¹, revised in December 2023. If the supplement does not arrive in 60 days, the manual says, FDA sends a "Failure to Respond" letter within five calendar days.

A harder case is a brand that leaves the market. A generic cannot copy updates to a label that no longer changes. A 2020 law, the MODERN Labeling Act¹², added section 503D to the drug law, letting FDA update labeling for generics whose brand was withdrawn for reasons other than safety or effectiveness, when, among other conditions, "updating the approved labeling would benefit the public health."

The 2011 decision and what followed

How FDA reads its own rules decided the 2011 case. The plaintiffs argued generic makers could have used the changes-being-effected process, which lets a company add or strengthen a warning before FDA signs off. The Court deferred to FDA, which "interprets the CBE regulation to allow changes to generic drug labels only when a generic drug manufacturer changes its label to match an updated brand-name label or to follow the FDA's instructions." It also accepted FDA's view that "Dear Doctor" letters count as labeling and so cannot carry new warnings the brand lacks.

Justices in the majority acknowledged the result was hard on patients. Had they taken the brand, their suits could have gone forward under an earlier precedent. "We acknowledge the unfortunate hand that federal drug regulation has dealt" them and others in their position, it wrote, but left any change to Congress and FDA. Two years later, in a case about the anti-inflammatory sulindac, the Court held in a 2013 decision² that "state-law design-defect claims that turn on the adequacy of a drug's warnings are pre-empted" as well.

FDA responded with a proposed rule on Nov. 13, 2013¹⁷. It would have let generic holders distribute revised safety labeling that temporarily differed from the brand's after filing a changes-being-effected supplement, to "create parity among application holders." The notice said about 80 percent of all drugs dispensed were generics. FDA withdrew the proposal on Dec. 14, 2018¹⁸, "in light of concerns expressed by commenters and considerations regarding Agency resources." The sameness rule stands as it did in 2011.

What the next user fee deal would change

FDA's proposed GDUFA IV commitment letter¹⁶, for fiscal 2028 through 2032, keeps the rule and speeds up the reviewing. Labeling reviewers would strive to issue any first-cycle DRL by the midpoint of review, do a second labeling review before the goal date when an applicant answers promptly, "strive to review revised labeling submitted by the applicant in response to changes to the RLD labeling within 30 days of receipt," and send comments on prescribing information in track-changes format. GDUFA III expires in September 2027.

Readers who want to compare a generic's insert with its brand's can find both on DailyMed, as described in how to look up a drug on DailyMed, and GxRadar's guide to what a prescription drug label contains walks through the sections. Questions about what a label means for a particular person are for a pharmacist or prescriber.